



Form PTO-1449 (modified)

Office of Patents and Publications for Applicant's

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

UTSC:664

Serial No.

09/599,152

Applicant

David Yang *et al.*

Filing Date:

June 21, 2000

Group:

1616

7/6/8

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
A	A46	4,279,992	7/21/81	Boguslaski <i>et al.</i>	435	7	10/23/79
	A47	4,789,542	12/06/88	Goodman and Knapp, Jr.	424	1.1	4/29/86
	A48	4,824,659	4/25/89	Hawthorne	424	1.1	6/07/85
	A49	5,013,556	5/07/91	Woodle <i>et al.</i>	424	450	10/20/89
	A50	5,356,793	10/18/94	Koezuka <i>et al.</i>	435	32	2/01/91
	A51	5,643,883	6/01/97	Marchase and Darbha	514	23	1/19/95
	A52	5,688,487	11/18/97	Linder <i>et al.</i>	424	1.65	6/06/95
	A53	5,834,266	11/10/98	Crabtree <i>et al.</i>	435	172.3	8/18/94
	A54	5,877,289	3/02/99	Thorpe and Edgington	530	387.1	6/07/95
	A55	5,891,468	4/06/99	Martin and Zalipsky	424	450	10/10/97
	A56	6,033,884	3/07/00	Woo <i>et al.</i>	435	172.3	12/14/93
	A57	6,054,436	4/25/00	Crabtree <i>et al.</i>	514	31	5/29/98

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
B	B11	WO 98/08859	3/05/98	WIPO			English

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
C	C342	Boersma <i>et al.</i> , "Quantification of apoptotic cells with fluorescein isothiocyanate-labeled annexin V in Chinese hamster ovary cell cultures treated with cisplatin," <i>Cytometry</i> , 24:123-130, 1996.
C	C343	Cafaggi <i>et al.</i> , "Synthesis and antitumor activity of a new cis-diammineplatinum (III) complex containing procaine hydrochloride," <i>Anticancer Research</i> , 12:2285-2292, 1992.

25485041.1

EXAMINER:

DATE CONSIDERED:

5/13/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)		Atty. Docket No. UTSC:664	Serial No. 09/599,152
Office of Patents and Publications for Applicant's		Applicant David Yang <i>et al.</i>	
INFORMATION DISCLOSURE STATEMENT		Filing Date: June 21, 2000	Group: 1616 1618
(Use several sheets if necessary)			
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
WC	C344	Cammisuli <i>et al.</i> , "SDZ 281-977: a modified partial structure of lavendustin A that exerts potent and selective antiproliferative activities in vitro and in vivo," <i>Int J Cancer</i> , 65:351-359, 1996.
	C345	Chakrabarti <i>et al.</i> , "Interaction of the antitumor antibiotic chromomycin A3 with glutathione, a sulfhydryl agent, and the effect upon its DNA binding properties," <i>Biochemical Pharmacology</i> , 56:1471-1479, 1998.
	C346	Connors, "Anticancer drug development: the way forward," <i>The Oncologist</i> , 1:180-181, 1996.
	C347	Guo and Gallo, "Selective protection of 2', 2'-difluorodeoxycytidine (Gemcitabine)," <i>J Org Chem</i> , 64:8319-8322, 1999.
	C348	Hirsch <i>et al.</i> , "PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection," <i>Experimental Cell Research</i> , 241:426-434, 1998.
	C349	Hjarnaa <i>et al.</i> , "CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo," <i>Cancer Res.</i> , 59:5751-5757, 1999.
	C350	Inoue <i>et al.</i> , "Evaluation of In-111 DTPA-paclitaxel scintigraphy to predict response on murine tumors to paclitaxel," <i>Annals of Nuclear Medicine</i> , 13(3):169-174, 1999.
	C351	Jiang <i>et al.</i> , "Antitumor activity of didemnin B in the human tumor stem cell assay," <i>Cancer Chemother Pharmacol</i> , 11:1-4, 1983.
	C352	Jiang <i>et al.</i> , "3-(Iodoacetamido)-benzoylurea: a novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells," <i>Cancer Res.</i> , 58:5389-5395, 1998.
	C353	LeClerc and Cedergren, "Modeling RNA-ligand interactions: the rev-binding element RNA-aminoglycoside complex," <i>J Med Chem</i> , 41:175-182, 1998.
	C354	Lundberg <i>et al.</i> , "Conjugation of an anti-B-cell lymphoma monoclonal antibody, LL2, to long-circulating drug-carrier lipid emulsions," <i>J Pharm Pharmacol</i> , 51:1099-1105, 1999.
	C355	McGahon <i>et al.</i> , "Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system," <i>British Journal of Haematology</i> , 101:539-547, 1998.
29	C356	Meyer <i>et al.</i> , "Tryptophan hydrolase antibodies used in the diagnosis of carcinoid," <i>Hepato-Gastroenterology</i> , 45:1522-1526, 1998.


25485041.1

EXAMINER:

DATE CONSIDERED:

5/13/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified) List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Atty. Docket No. UTSC:664	Serial No. 09/599,152
		Applicant David Yang <i>et al.</i>	
		Filing Date: June 21, 2000	Group: 1616 1618
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C357	Murray <i>et al.</i> , "Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer," <i>Journal of Pathology</i> , 185:256-261, 1998.
	C358	Palyi <i>et al.</i> , "Effects of methylacetylenic putrescine, and ornithine decarboxylase inhibitor and potential novel anticancer agent, on human and mouse cancer cell lines," <i>Anti-Cancer Drugs</i> , 10:103-111, 1999.
	C359	Pavicevic <i>et al.</i> , "Serum tumor marker CYFRA 21-1 in the diagnostics of NSCLC lung cancer," <i>Coll Antropol</i> , 22(2):629-635, 1998.
	C360	Pavlik <i>et al.</i> , "Properties of anticancer agents relevant to in vitro determinations of human tumor cell sensitivity," <i>Cancer Chemother Pharmacol</i> , 11:8-15, 1983.
	C361	Rasey <i>et al.</i> , "Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia," <i>Int J Radiation Oncology Biol Phys</i> , 17:985-991, 1989.
	C362	Rasey <i>et al.</i> , "Characteristics of the binding of labeled fluoromisonidazole in cells in vitro," <i>Radiation Research</i> , 122:301-308, 1990.
	C363	Reutelingsperger and van Heerde, "Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis," <i>Cell Mol Life Sci</i> , 53:527-532, 1997.
	C364	Thompson, "Apoptosis in the pathogenesis and treatment of disease," <i>Science</i> , 267:1456-1462, 1995.
	C365	Tolomeo <i>et al.</i> , "The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis," <i>Cell Death and Differentiation</i> , 5:735-742, 1998.
	C366	Van den Eijnde <i>et al.</i> , "In situ detection of apoptosis during embryogenesis with annexin V: from whole mount to ultrastructure," <i>Cytometry</i> , 29:313-320, 1997.
	C367	Wright <i>et al.</i> , "Aminoglycoside antibiotics: structures, functions, and resistance," In: <i>Resolving the Antibiotic Paradox</i> , Rosen and Mobashery eds, Kluwer Academic/Plenum Pub NY, 1998.
	C368	Yoshinari <i>et al.</i> , "Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I," <i>Cancer Res.</i> , 59:4271-4275, 1999.

25485041.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

UTSC:664

Serial No.

09/599,152

List of Patents and Publications for Applicant's

Applicant

David Yang *et al.*

## INFORMATION DISCLOSURE STATEMENT

FEB 25 2005

(Use several sheets if necessary)

Filing Date:

June 21, 2000

Group:

1616

1618

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A46	4,279,992	7/21/81	Boguslaski <i>et al.</i>	435	7	10/23/79
	A47	4,789,542	12/06/88	Goodman and Knapp, Jr.	424	1.1	4/29/86
	A48	4,824,659	4/25/89	Hawthorne	424	1.1	6/07/85
	A49	5,013,556	5/07/91	Woodle <i>et al.</i>	424	450	10/20/89
	A50	5,356,793	10/18/94	Koezuka <i>et al.</i>	435	32	2/01/91
	A51	5,643,883	6/01/97	Marchase and Darbha	514	23	1/19/95
	A52	5,688,487	11/18/97	Linder <i>et al.</i>	424	1.65	6/06/95
	A53	5,834,266	11/10/98	Crabtree <i>et al.</i>	435	172.3	8/18/94
	A54	5,877,289	3/02/99	Thorpe and Edgington	530	387.1	6/07/95
	A55	5,891,468	4/06/99	Martin and Zalipsky	424	450	10/10/97
	A56	6,033,884	3/07/00	Woo <i>et al.</i>	435	172.3	12/14/93
	A57	6,054,436	4/25/00	Crabtree <i>et al.</i>	514	31	5/29/98

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B11	WO 98/08859	3/05/98	WIPO			English

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C342	Boersma <i>et al.</i> , "Quantification of apoptotic cells with fluorescein isothiocyanate-labeled annexin V in Chinese hamster ovary cell cultures treated with cisplatin," <i>Cytometry</i> , 24:123-130, 1996.
	C343	Cafaggi <i>et al.</i> , "Synthesis and antitumor activity of a new cis-diammineplatinum (III) complex containing procaine hydrochloride," <i>Anticancer Research</i> , 12:2285-2292, 1992.

25485041.1

EXAMINER:

DATE CONSIDERED:

5/13/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:664

09/599,152

List of Patents and Publications for Applicant's

Applicant

David Yang *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:

June 21, 2000

Group:

1616

1618

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C344	Cammisuli <i>et al.</i> , "SDZ 281-977: a modified partial structure of lavendustin A that exerts potent and selective antiproliferative activities in vitro and in vivo," <i>Int J Cancer</i> , 65:351-359, 1996.
	C345	Chakrabarti <i>et al.</i> , "Interaction of the antitumor antibiotic chromomycin A3 with glutathione, a sulfhydryl agent, and the effect upon its DNA binding properties," <i>Biochemical Pharmacology</i> , 56:1471-1479, 1998.
	C346	Connors, "Anticancer drug development: the way forward," <i>The Oncologist</i> , 1:180-181, 1996.
	C347	Guo and Gallo, "Selective protection of 2', 2'-difluorodeoxycytidine (Gemcitabine)," <i>J Org Chem</i> , 64:8319-8322, 1999.
	C348	Hirsch <i>et al.</i> , "PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection," <i>Experimental Cell Research</i> , 241:426-434, 1998.
	C349	Hjarnaa <i>et al.</i> , "CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo," <i>Cancer Res.</i> , 59:5751-5757, 1999.
	C350	Inoue <i>et al.</i> , "Evaluation of In-111 DTPA-paclitaxel scintigraphy to predict response on murine tumors to paclitaxel," <i>Annals of Nuclear Medicine</i> , 13(3):169-174, 1999.
	C351	Jiang <i>et al.</i> , "Antitumor activity of didemnin B in the human tumor stem cell assay," <i>Cancer Chemother Pharmacol</i> , 11:1-4, 1983.
	C352	Jiang <i>et al.</i> , "3-(Iodoacetamido)-benzoylurea: a novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells," <i>Cancer Res.</i> , 58:5389-5395, 1998.
	C353	LeClerc and Cedergren, "Modeling RNA-ligand interactions: the rev-binding element RNA-aminoglycoside complex," <i>J Med Chem</i> , 41:175-182, 1998.
	C354	Lundberg <i>et al.</i> , "Conjugation of an anti-B-cell lymphoma monoclonal antibody, LL2, to long-circulating drug-carrier lipid emulsions," <i>J Pharm Pharmacol</i> , 51:1099-1105, 1999.
	C355	McGahon <i>et al.</i> , "Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system," <i>British Journal of Haematology</i> , 101:539-547, 1998.
	C356	Meyer <i>et al.</i> , "Tryptophan hydrolase antibodies used in the diagnosis of carcinoid," <i>Hepato-Gastroenterology</i> , 45:1522-1526, 1998.

25485041.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP § 909; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:664

09/599,152

List of Patents and Publications for Applicant's

Applicant

David Yang *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:

June 21, 2000

Group:

1616

1618

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1













Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C357	Murray <i>et al.</i> , "Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer," <i>Journal of Pathology</i> , 185:256-261, 1998.
	C358	Palyi <i>et al.</i> , "Effects of methylacetylenic putrescine, and ornithine decarboxylase inhibitor and potential novel anticancer agent, on human and mouse cancer cell lines," <i>Anti-Cancer Drugs</i> , 10:103-111, 1999.
	C359	Pavicevic <i>et al.</i> , "Serum tumor marker CYFRA 21-1 in the diagnostics of NSCLC lung cancer," <i>Coll Antropol</i> , 22(2):629-635, 1998.
	C360	Pavlik <i>et al.</i> , "Properties of anticancer agents relevant to in vitro determinations of human tumor cell sensitivity," <i>Cancer Chemother Pharmacol</i> , 11:8-15, 1983.
	C361	Rasey <i>et al.</i> , "Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia," <i>Int J Radiation Oncology Biol Phys</i> , 17:985-991, 1989.
	C362	Rasey <i>et al.</i> , "Characteristics of the binding of labeled fluoromisonidazole in cells in vitro," <i>Radiation Research</i> , 122:301-308, 1990.
	C363	Reutelingsperger and van Heerde, "Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis," <i>Cell Mol Life Sci</i> , 53:527-532, 1997.
	C364	Thompson, "Apoptosis in the pathogenesis and treatment of disease," <i>Science</i> , 267:1456-1462, 1995.
	C365	Tolomeo <i>et al.</i> , "The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis," <i>Cell Death and Differentiation</i> , 5:735-742, 1998.
	C366	Van den Eijnde <i>et al.</i> , "In situ detection of apoptosis during embryogenesis with annexin V: from whole mount to ultrastructure," <i>Cytometry</i> , 29:313-320, 1997.
	C367	Wright <i>et al.</i> , "Aminoglycoside antibiotics: structures, functions, and resistance," In: <i>Resolving the Antibiotic Paradox</i> , Rosen and Mobashery eds, Kluwer Academic/Plenum Pub NY, 1998.
	C368	Yoshinari <i>et al.</i> , "Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I," <i>Cancer Res.</i> , 59:4271-4275, 1999.

25485041.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:664

09/599,152

Office of Patents and Publications for Applicant's

Applicant

David Yang *et al.*

## INFORMATION DISCLOSURE STATEMENT

Filing Date:

Group:

June 21, 2000

1616

1618

(Use several sheets if necessary)

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 1

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A44	4,988,496	02/29/91	Srinivasan <i>et al.</i>	424	1.53	5/31/88
	A45	5,268,163	12/07/93	Verbruggen	424	1.1	4/10/91

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B8	WO 01/80906	11/01/01	PCT			English
	B9	WO 01/91807	12/06/01	PCT			English
	B10	WO 91/16076	10/31/91	PCT			English

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C295	Alauddin and Conti, "Synthesis and preliminary evaluation of 9-(4-{ <sup>18</sup> F}-Fluoro-3-Hydroxymethylbutyl)guanine ([ <sup>18</sup> F]FHBG): a new potential imaging agent for viral infection and gene therapy," <i>Nucl. Med. Biol.</i> , 25:175-180, 1998.
	C296	Alauddin <i>et al.</i> , "9-[(3- <sup>18</sup> F)-fluoro-1-hydroxy-2-propoxy)methyl]guanine ([ <sup>18</sup> F]-FHPG): a potential imaging agent of viral infection and gene therapy using PET," <i>Nucl. Med. Biol.</i> , 23:787-792, 1996.
	C297	Alauddin <i>et al.</i> , "Evaluation of 9-[(3- <sup>18</sup> F)-fluoro-1-hydroxy-2-propoxy)methyl]guanine ([ <sup>18</sup> F]-FHPG) in vitro and in vivo as probe for PET imaging of gene incorporation and expression in tumors," <i>Nucl. Med. Biol.</i> , 26:371-376, 1999.
	C298	Alauddin <i>et al.</i> , "Receptor mediated uptake of a radiolabeled contrast agent sensitive to $\beta$ -galactosidase activity," <i>Nucl. Med. Biol.</i> , 30:261-265, 2002.
	C299	Appelbaum <i>et al.</i> , "The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia," <i>Transplantation</i> , 54(5):829-833, 1992.

25418818.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:664

09/599,152

U.S. Patent and Publications for Applicant's

Applicant

David Yang *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:

June 21, 2000

Group:

1616

1618

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C300	Bertolini <i>et al.</i> , "Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma," <i>Br. J. Haematol.</i> , 106:5045, 1999.
	C301	Bormans <i>et al.</i> , "Synthesis and biological characteristics of the four stereoisomers of 99mTc-N, N'-bis-(mercaptoacetyl)2,3-diaminopropanoate," <i>Int. J. Rad. Appl. Instrum. B.</i> , 17(5):499-506, 1990.
	C302	Burian <i>et al.</i> , <i>Acta Otolaryngol.</i> , 119:289-292, 1999.
	C303	Cao, "Therapeutic potentials of angiostatin in the treatment of cancer," <i>Haematologica</i> , 84:643-650, 1999.
	C304	Deveraux and Reed, "IAP family proteins-suppressors of apoptosis," <i>Genes and Development</i> , 13:239-252, 1999.
	C305	Frisch and Screaton, "Anoikis mechanisms," <i>Curr. Opin. Cell Biol.</i> , 13:555-562, 2001.
	C306	Gambhir <i>et al.</i> , "A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography," <i>Proc. Natl. Acad. Sci., USA</i> , 97(6):2785-2790, 2000.
	C307	Gambhir <i>et al.</i> , "Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography," <i>Proc. Natl. Acad. Sci., USA</i> , 96:2333-2338, 1999.
	C308	Gambhir <i>et al.</i> , "Imaging of adenoviral-directed herpes simplex virus type 1 thymidine kinase reporter gene expression in mice with radiolabeled ganciclovir," <i>J. Nucl. Med.</i> , 39:2003-2011, 1998.
	C309	Green and Evan, "A matter of life and death," <i>Cancer Cell</i> , 1:19-30, 2002.
	C310	Inoue <i>et al.</i> , "The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy," <i>Clin. Cancer Res.</i> , 6:4866-4873, 2000.
	C311	Ionov <i>et al.</i> , "Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution," <i>Proc. Natl. Acad. Sci., USA</i> , 97(20):10872-10877, 2000.
	C312	Iyer <i>et al.</i> , "8-[18F]Fluoropenciclovir: an improved reporter probe for imaging HSV1-tk reporter gene expression in vivo using PET," <i>J. Nucl. Med.</i> , 42(1):96-105, 2001.
	C313	Kao <i>et al.</i> , "Detection of esophageal carcinoma using Tc-99m MIBI SPECT imaging," <i>Clin. Nucl. Med.</i> , 19(12):1069-1074, 1994.

25418818.1

EXAMINER:

DATE CONSIDERED:

5/13/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:664

09/599,152

List of Patents and Publications for Applicant's

Applicant

David Yang *et al.*

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

June 21, 2000

Group:

1616/1618

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C314	Kao <i>et al.</i> , "Relationship of alveolar permeability and lung inflammation in patients with active diffuse infiltrative lung disease detected by 99Tcm-DTPA radioaerosol inhalation lung scintigraphy and quantitative 67Ga lung scans," <i>Nucl. Med. Commun.</i> , 15(10):850-854, 1994.
	C315	Kao <i>et al.</i> , "Tc-99m MIBI uptake in breast carcinoma and axillary lymph node metastases," <i>Clin. Nuc. Med.</i> , 19(10):898-900, 1994.
	C316	Lin <i>et al.</i> , "The role of Tc-99m MDP and Ga-67 imaging in the clinical evaluation of malignant fibrous histiocytoma," <i>Clin. Nuc. Med.</i> , 19(11):996-1000, 1994.
	C317	Liu <i>et al.</i> , "Apoptotic signals delivered through the T-cell receptor of a T-cell hybrid require the immediate-early gene nur77," <i>Nature</i> , 367(6460):281-284, 1994.1994.
	C318	Liu <i>et al.</i> , "Detection of anaerobic odontogenic infections by fluorine-18 fluoromisonidazole," <i>Eur. J. Nucl. Med.</i> , 23(10):1384-1387, 1996.
	C319	Macapinlac <i>et al.</i> , "Callium-67-citrate imaging in nuclear oncology," <i>Nucl. Med. Biol.</i> , 21(5):731-738, 1994.
	C320	Makin and Hickman, "Apoptosis and cancer chemotherapy," <i>Cell Tissue Res.</i> , 301:143-152, 2000.
	C321	Martin <i>et al.</i> , "Noninvasive detection of hypoxic myocardium using fluorine-18 fluoromisonidazole and positron emission tomography," <i>J. Nucl. Med.</i> , 33(12):2202-2208, 1992.
	C322	Meredith <i>et al.</i> , "Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49," <i>J. Nucl. Med.</i> , 35(6):1017-1022, 1994.
	C323	Namavari <i>et al.</i> , "Synthesis of 8-[18F]Fluoroguanin derivatives: in vivo probes for imaging gene expression with positron emission tomography," <i>Nucl. Med. Biol.</i> , 27:157-162, 2000.
	C324	Reed, "Apoptosis-targeted therapies for cancer," <i>Cancer Cell</i> , 3:17-22, 2003.
	C325	Smalley <i>et al.</i> , "Localization of fluorescent compounds in the firefly light organ," <i>J. Histochem. Cytochem.</i> , 28(4):323-329, 1980.
	C326	Smith <i>et al.</i> , "Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma," <i>J. Clin. Oncol.</i> , 18(10):2046-2052, 2000.

25418818.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609, DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.  
UTSC:664Serial No.  
09/599,152

List of Patents and Publications for Applicant's

Applicant  
David Yang *et al.*

## INFORMATION DISCLOSURE STATEMENT

Filing Date:  
June 21, 2000Group:  
1616 1618

(Use several sheets if necessary)

U.S. Patent Documents  
See Page 1Foreign Patent Documents  
See Page 1Other Art  
See Page 1

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C327	Sun <i>et al.</i> , "Idium(III) and Gallium(III) Complexes of Bis(aminoethanethiol) Ligands with Different Denticities: Stabilities, Molecular Modeling, and in Vivo Behavior," <i>Journal of Medicinal Chemistry</i> , 39(2):458(1996).
	C328	Taggart <i>et al.</i> , <i>Human Mutation</i> , 13(3):210-220, 1999.
	C329	Tschopp <i>et al.</i> , "Apoptosis: silencing the death receptors," <i>Curr. Biol.</i> , 9:R381-R384, 1999.
	C330	Ugurel <i>et al.</i> , "Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival," <i>J. Clin. Oncol.</i> , 19(2):577-583, 2001.
	C331	Verbruggen <i>et al.</i> , "Tc-99m-L,L-ethylenedicysteine: A renal imaging agent. I. Labelling and evaluation in animals," <i>J Nucl Med</i> , 33:551-557, 1992.
	C332	Yaghoubi <i>et al.</i> , "Human pharmacokinetic and dosimetry studies of {18F}FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression," <i>J. Nucl. Med.</i> , 42:1225-1234, 2001.
	C333	Ye <i>et al.</i> , "TRAF family proteins interact with the common neurotrophin receptor and modulate apoptosis induction," <i>J. Biol. Chem.</i> , 274(42):30202-30208, 1999.
	C334	Yeh <i>et al.</i> , "Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma," <i>Eur. J. Nucl. Med.</i> , 23(10):1378-1383, 1996.
	C335	Yen <i>et al.</i> , "A comparative study of evaluating renal scars by 99mTc-DSMA planar and SPECT renal scans, intravenous urography, and ultrasonography," <i>Ann. Nucl. Med.</i> , 8(2):147-152, 1994.
	C336	Yen <i>et al.</i> , "Technetium-99m-DMSA renal SPECT in diagnosing and monitoring pediatric acute pyelonephritis," <i>J. Nucl. Med.</i> , 37(8):1349-1353, 1996.
	C337	Yen <i>et al.</i> , "The role of technetium-99m sestamibi whole-body scans in diagnosing metastatic Hurthle cell carcinoma of the thyroid gland after total thyroidectomy: a comparison with iodine-131 and thallium-201 whole-body scans," <i>Eur. J. Nucl. Med.</i> , 21(9):980-983, 1994.
	C338	Co-Pending U.S. Patent Application 10/672,763 filed 9/26/03 (UTSC:664USC1).
	C339	Co-Pending U.S. Patent Application 10/672,142 filed 9/26/03 (UTSC:664USC2).
	C340	Co-Pending U.S. Patent Application 10/703,405 filed 11/07/03 (UTSC:758).
	C341	Co-Pending U.S. Patent Application 10/732,919 filed 12/10/03 (UTSC:841US).

25418818.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.